

# Lianne Kearsley-Fleet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7361163/publications.pdf>

Version: 2024-02-01

55  
papers

1,919  
citations

377584

21  
h-index

299063

42  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2946  
citing authors

#	ARTICLE	IF	CITATIONS
1	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. <i>Rheumatology</i> , 2022, 61, 2524-2534.	0.9	9
2	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.5	130
3	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
4	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 998-1005.	0.5	12
5	OA14aâ€fOutcomes after switching from etanercept originator to its biosimilar (SB4) for the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
6	OA14bâ€fEtanercept originator versus its biosimilar (SB4) for the treatment of rheumatoid arthritis. Are they truly similar?. <i>Rheumatology</i> , 2022, 61, .	0.9	0
7	OA21â€fContinuing specialist care beyond age 16 in young people with juvenile idiopathic arthritis: a descriptive study using electronic health records in England. <i>Rheumatology</i> , 2022, 61, .	0.9	0
8	OA01â€fSafety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Rheumatology</i> , 2022, 61, .	0.9	0
9	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the â€fJAK-potâ€™ collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366.	0.5	48
10	O32â€fSerious infection with tocilizumab compared to TNF-inhibitors and other bDMARDs in rheumatoid arthritis patients: does line of therapy matter?. <i>Rheumatology</i> , 2021, 60, .	0.9	0
11	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
12	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.5	496
13	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	2.2	38
14	The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. <i>Rheumatology</i> , 2020, 59, 1391-1397.	0.9	12
15	O27â€fEarly experience with JAK inhibitor prescribing in the UK: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Rheumatology</i> , 2020, 59, .	0.9	1
16	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , 2020, 80, 849-857.	4.9	20
17	Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e217-e226.	2.2	25
18	Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2019, 58, 80-85.	0.9	33

#	ARTICLE	IF	CITATIONS
19	Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. <i>Rheumatology</i> , 2019, 58, 94-102.	0.9	20
20	Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2019, 59, 559-567.	0.9	1
21	P20â€fBiosimilar use in children and young people with juvenile idiopathic arthritis in a real-world setting in the United Kingdom. <i>Rheumatology</i> , 2019, 58, .	0.9	0
22	Not all moderate disease is the same â€“ Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. <i>PLoS ONE</i> , 2019, 14, e0215999.	1.1	13
23	O22â€fFrequency and reasons for switching back to etanercept originator following initial switch to etanercept biosimilar. <i>Rheumatology</i> , 2019, 58, .	0.9	2
24	Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2019, 58, 1453-1458.	0.9	11
25	SAT0141â€f...FREQUENCY AND REASONS FOR SWITCHING BACK TO BIOLOGIC ORIGINATOR FOLLOWING INITIAL SWITCH TO BIOLOGIC BIOSIMILAR. , 2019, , .		0
26	AB0434â€f...EARLY EXPERIENCE WITH JAK INHIBITOR PRESCRIBING IN THE UK: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS (BSRBR-RA). , 2019, , .		1
27	Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. <i>Rheumatology</i> , 2019, 58, 331-335.	0.9	27
28	Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. <i>RMD Open</i> , 2018, 4, e000596.	1.8	38
29	The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBRâ€fRA. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 556-558.	1.3	13
30	Long-term persistence with rituximab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1089-1096.	0.9	22
31	Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 53-60.	1.6	26
32	P33â€fFirst diagnosis of uveitis is not higher among juvenile idiopathic arthritis patients receiving etanercept compared to methotrexate. <i>Rheumatology</i> , 2018, 57, .	0.9	0
33	243â€fLongâ€fTerm risk of serious infections in patients with rheumatoid arthritis treated with rituximab: five year data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBRâ€fRA). <i>Rheumatology</i> , 2018, 57, .	0.9	0
34	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1405-1412.	0.5	117
35	O87â€fRefractory disease in rheumatoid arthritis: results from the British Society of Rheumatology Biologics Register for rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	1
36	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	1.8	29

#	ARTICLE	IF	CITATIONS
37	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 241-250.	1.0	40
38	How common is remission in juvenile idiopathic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 331-337.	1.6	60
39	Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , 2017, 102, 206.2-207.	1.0	14
40	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. <i>Pediatric Rheumatology</i> , 2017, 15, 31.	0.9	27
41	Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. <i>Rheumatology</i> , 2017, 56, kew493.	0.9	9
42	Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000273.	1.8	8
43	Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Rheumatology</i> , 2016, 55, 840-847.	0.9	33
44	Risk of <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor I±: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis: Table 1. <i>Rheumatology</i> , 2016, 55, 1336-1337.	0.9	15
45	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. <i>Rheumatology</i> , 2016, 55, 2033-2039.	0.9	67
46	Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. <i>Rheumatology</i> , 2016, 55, 1556-1565.	0.9	38
47	Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 2487-2494.	2.9	45
48	Spatiotemporal trends in the discovery of new swine infectious agents. <i>Veterinary Research</i> , 2015, 46, 114.	1.1	14
49	PP3. Standardized mortality rates are increased in patients with severe JIA. <i>Rheumatology</i> , 2015, 54, ii6-ii6.	0.9	2
50	274. Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from Two UK Paediatric Biologic Registers. <i>Rheumatology</i> , 2015, , .	0.9	0
51	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	0.9	22
52	O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	0.9	0
53	Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Rheumatology</i> , 2015, 54, 1279-1285.	0.9	11
54	Prevalence and risk factors for canine epilepsy of unknown origin in the UK. <i>Veterinary Record</i> , 2013, 172, 338-338.	0.2	168

#	ARTICLE	IF	CITATIONS
55	Country-Level Factors Associated With COVID-19-Related Death in People With Rheumatic Disease: Results From the COVID-19 Global Rheumatology Alliance Registry. SSRN Electronic Journal, 0, , .	0.4	0